Published Paper Details:

The present study focuses on the development and validation of a Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) method for the simultaneous estimation of Losartan Potassium and Enalapril Maleate in pharmaceutical dosage forms. The analytical method was developed to provide a simple, precise, accurate, and cost-effective technique suitable for routine quality control analysis. Chromatographic separation was achieved using a C18 column with a mobile phase consisting of buffer and acetonitrile (60:40 v/v, pH 4.5 adjusted with orthophosphoric acid) at a flow rate of 1.0 mL/min. The detection wavelength was set at 235 nm, providing well-resolved and symmetrical peaks for both analytes with retention times of 3.15 min for Enalapril Maleate and 5.42 min for Losartan Potassium. The developed method was validated as per ICH Q2 (R1) guidelines, fulfilling parameters such as specificity, linearity, precision, accuracy, robustness, and system suitability. Linearity was established in the range of 5-15 ?g/mL for Enalapril Maleate and 25-75 ?g/mL for Losartan Potassium, with correlation coefficients exceeding 0.999. The recovery results were within 98-102%, confirming method accuracy and reproducibility. The validated RP-HPLC method proved to be reliable for the simultaneous determination of Losartan and Enalapril, making it highly applicable for routine pharmaceutical quality control.